Skip to main content

AI Bias Analysis

4 models · Takes ~15 seconds

Stat News

STAT+: Merck-Kelun lung cancer drug cut risk of tumor progression by 65%, ASCO abstract shows

STAT+: Merck-Kelun lung cancer drug cut risk of tumor progression by 65%, ASCO abstract shows
ShareXFacebook

A type of targeted chemotherapy developed by China-based Kelun-Biotech and licensed to Merck cut the risk of tumor progression by 65% in patients with lung cancer, according to Phase 3…

S

Source

Stat News

Read full article at Stat News

Opens original article in a new tab

Advertisement

Related Health Stories

Migraine With Aura Tied to Higher Stroke Risk
MedPage Today

Migraine With Aura Tied to Higher Stroke Risk

(MedPage Today) -- Middle-aged and older adults who had migraine with aura had a greater risk of subsequent stroke, a study of 11,000 people showed. Over 6 years, migraine with aura was associated with a 73% higher risk of ischemic stroke compared...

Read more →
Advertisement